The NF-κB inhibitor-treated DCs were tested in 18 ACPA+ RA patients, 9 of whom were intradermally injected with low-dose and 9 with high-dose Rheumavax [28]. The gene discussed is NFKB1; the disease is rheumatoid arthritis.